Ajanta is one of the largest international pharmaceutical companies headquartered in Mumbai, India. It operates since 1973 and is engaged in manufacture, research and development of various pharmaceutical formulations, focusing on synergistic combinations and generic drugs in such therapeutic segments as cardiovascular, musculoskeletal, ophthalmology, dermatology, gastroenterology and pulmonology.
Ajanta has a research and development center for active pharmaceutical ingredients synthesis and finished formulations of various dosage forms. It also has four manufacturing facilities in Aurangabad, India, and one in Mauritius. The company’s facilities are certified for Good Manufacturing Practice required by WHO. The Mauritius manufacturing facility is a wholly-owned subsidiary, which occupies solely with production of formulations. Three out of four manufacturing facilities located in India, manufacture finished formulations and one of them – active pharmaceutical ingredients. Two more facilities for formulations are under construction now.
The company’s manufacturing capabilities include a comprehensive range of dosage forms of allopathic drugs as tablets, capsules, IV drugs, ointments, powders, eye drops and nasal sprays sold in more than 40 countries of the world. Ajanta’s flagship formulation facility located in Paithan is approved by American FDA, UK MHRA and health authorities of Colombia and Brazil.
Ajanta develops and markets a wide range of innovative generic products. Its top brands include antimalaria drug Artefan, cardiovascular drug Met XL, dermatological composition Melacare, gastroenterological preparation Lafutax, musculoskeletal medication Feburic and ophthalmologic eye drops Nepaflam. It also has an integral global presence in erectile dysfunction treatment with its key brand Kamagra, the first branded generic that received the WHO pre-qualified. Ajanta was the first pharmaceutical company that introduced Sildenafil Citrate in the jelly form. Soon it introduced Kamagra chewable tablets and Kamagra Effervescent tablets with different flavors. These generic products received Marketing authorization in 11 countries of the EU under decentralized procedure.
Apart from the therapeutic products, Ajanta research and development center has developed some niche products in other areas, such as bile acid induced disease, gastric acid-related disease, pain and inflammation, gout, vertigo, constipation, nausea and vomiting, neurologic pain and muscle relaxant. Ajanta is also engaged in contract research for other healthcare companies.
Ajanta is constantly growing and developing being committed to improve the quality standards of its products by upgrading technology and implementing Current Good Manufacturing Practices. It is committed to patients care in India and is simultaneously opening new international markets in order to perform a mission to serve global healthcare needs.